COR.NYSECencora, INC

Form 4: Cencora Director Lauren M. Tyler Reports Acquisition of Common Stock

Sentiment:

SEC Form 4 Filing


Director Lauren M. Tyler reports acquiring 107 shares of Cencora, Inc. common stock on November 1, 2024, through a grant of restricted stock units.

Summary

  • Lauren M. Tyler, a director of Cencora, Inc., filed a Form 4 on November 5, 2024, reporting a transaction.
  • On November 1, 2024, Tyler acquired 107 shares of Cencora common stock at a price of $234.27 per share.
  • These shares were received as a grant of restricted stock units in lieu of a $25,000 quarterly cash retainer, as part of Cencora's Non-Employee Director Compensation Program.
  • Delivery of these shares is deferred until March 1, 2025.
  • Following the reported transaction, Tyler directly owns 1,883 shares of Cencora common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The director's stock acquisition is a routine event, but it can be interpreted as a sign of confidence in the company.

Positives

  • The acquisition of shares by a director signals confidence in the company's future.
  • The use of restricted stock units aligns the director's interests with those of the shareholders.

Future Outlook

The document does not contain any specific forward-looking statements regarding Cencora's future performance.

Industry Context

Director stock acquisitions are common in publicly traded companies and are often viewed as a positive sign by investors. Compensation packages including stock options and restricted stock units are frequently used to align the interests of directors and management with those of shareholders.

Comparison to Industry Standards

  • Director compensation packages vary across the pharmaceutical distribution industry.
  • Companies like McKesson and Cardinal Health also utilize a mix of cash and equity-based compensation for their directors.
  • The specific amount and structure of equity grants depend on factors such as company size, performance, and industry benchmarks.

Stakeholder Impact

  • The director's stock acquisition could have a slightly positive impact on shareholder sentiment.
  • The transaction has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

DateDescription
11/01/2024Transaction date: Acquisition of 107 shares of common stock.
11/05/2024Date of Form 4 filing.
03/01/2025Delivery date of shares deferred until this date.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.